For a study, it was determined that acute bacterial skin and skin structure infections (ABSSSIs) were prevalent infectious disorders that cost the healthcare system a lot of money. The cost-effectiveness of dalbavancin vs. standard of care (SoC) in the treatment of ABSSSI in a community-based healthcare system was compared. It was a 27-month retrospective study of adult patients with ABSSSI who were treated with dalbavancin or SoC. Patients were matched based on their age and BMI. The key outcome was the average net cost of care to the healthcare system per patient, which was determined by subtracting reimbursement payments from the overall care cost. The secondary outcome was the proportion of cases successfully treated, defined as no ABSSSI-related readmission within 30 days of starting treatment. 209 of the 418 matched patients were given SoC, and the rest of them were given dalbavancin. When comparing dalbavancin to SoC, the average total cost of care per patient was higher ($4770 vs. $2709, P<.0001). With dalbavancin, the average reimbursement per patient was $3084 vs. $2633 SoC (P=.527). With dalbavancin, the net cost was $1685 compared to $75 with SoC (P=.013). Overall, dalbavancin had a 74% success rate comparable to 85% for SoC (P=.004). For the treatment of ABSSSI, Dalbavancin was more expensive than SoC, with a higher 30-day readmission rate. Dalbavancin does not provide a cost or efficacy benefit.